We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+1.09%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$101M
AUM Growth
-$14.5M
Cap. Flow
-$1.16M
Cap. Flow %
-1.15%
Top 10 Hldgs %
56.77%
Holding
80
New
12
Increased
15
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
KLAC icon
KLA
KLAC
+$11.9M
2
OVV icon
Ovintiv
OVV
+$2.03M
3
NVCR icon
NovoCure
NVCR
+$1.22M
4
PRTA icon
Prothena Corp
PRTA
+$886K
5
GPCR icon
Structure Therapeutics
GPCR
+$792K

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$17.8M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$1.41M
3
UTHR icon
United Therapeutics
UTHR
+$971K
4
TVTX icon
Travere Therapeutics
TVTX
+$580K
5
MASI
Masimo
MASI
+$479K

Sector Composition

Rank Sector Weight
1 Healthcare 79.06%
2 Technology 14.1%
3 Energy 6.07%
4 Materials 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$15M 14.86%
323,358
-361,834
-53% -$17.8M
KLAC icon
2
KLA
KLAC
$278B
$14.2M 14.1%
+158,480
New +$11.9M
CORT icon
3
Corcept Therapeutics
CORT
$9.72B
$4.93M 4.9%
67,200
+1,200
+2% +$87K
OVV icon
4
Ovintiv
OVV
$16.2B
$4.09M 4.06%
107,500
+55,300
+106% +$2.03M
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.38B
$4.05M 4.02%
187,800
-75,600
-29% -$1.41M
NBIX icon
6
Neurocrine Biosciences
NBIX
$17.2B
$3.89M 3.86%
30,940
+700
+2% +$80.3K
PHR icon
7
Phreesia
PHR
$662M
$3.26M 3.24%
114,700
– –
PRTA icon
8
Prothena Corp
PRTA
$453M
$2.74M 2.72%
451,019
+118,045
+35% +$886K
PTGX icon
9
Protagonist Therapeutics
PTGX
$9.06B
$2.65M 2.63%
48,000
-2
-0% -$96
STOK icon
10
Stoke Therapeutics
STOK
$1.81B
$2.38M 2.37%
210,000
-5
-0% -$47
ELUT icon
11
Elutia
ELUT
$42M
$2.29M 2.28%
1,159,059
-28,676
-2% -$58K
CSTL icon
12
Castle Biosciences
CSTL
$733M
$2.26M 2.24%
110,600
+22,196
+25% +$411K
QDEL icon
13
QuidelOrtho
QDEL
$1.19B
$2.09M 2.08%
72,548
+4,929
+7% +$146K
EQT icon
14
EQT Corp
EQT
$31B
$2.02M 2.01%
34,619
– –
HROW icon
15
Harrow
HROW
$1.74B
$1.83M 1.82%
60,000
-12,910
-18% -$347K
NVCR icon
16
NovoCure
NVCR
$1.84B
$1.8M 1.79%
101,000
+70,000
+226% +$1.22M
AXGN icon
17
Axogen
AXGN
$2.12B
$1.75M 1.73%
161,000
– –
BDSX icon
18
Biodesix
BDSX
$209M
$1.62M 1.61%
286,806
– –
TVTX icon
19
Travere Therapeutics
TVTX
$5.27B
$1.52M 1.51%
103,000
-35,000
-25% -$580K
FHTX icon
20
Foghorn Therapeutics
FHTX
$305M
$1.46M 1.45%
310,930
– –
ALKS icon
21
Alkermes
ALKS
$8.79B
$1.43M 1.42%
50,000
– –
MASI
22
DELISTED
Masimo
MASI
$1.39M 1.38%
8,280
-3,000
-27% -$479K
QURE icon
23
uniQure
QURE
$2.77B
$1.38M 1.37%
98,697
+10,000
+11% +$135K
UTHR icon
24
United Therapeutics
UTHR
$22.7B
$1.22M 1.21%
4,250
-3,250
-43% -$971K
DCGO icon
25
DocGo
DCGO
$64.3M
$1.2M 1.19%
764,062
-100,000
-12% -$186K
1
2 3 4

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Birchview Capital held 80 positions worth $101M, down 13% from $115M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Birchview Capital's Q2 2025 filing shows 12 new, 15 increased, 13 reduced and 9 closed positions. Its largest new stake was KLA: 158,480 shares worth $14.2M. The largest sale was Bristol-Myers Squibb, an estimated $17.8M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 96% a quarter earlier, followed by Technology and Energy.

  • Birchview Capital's largest Q2 2025 buy was KLA: 158,480 shares worth $14.2M.
  • Birchview Capital added most to Ovintiv in Q2 2025, an estimated $2.03M increase.
  • Birchview Capital's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $17.8M.
  • Birchview Capital fully exited SpringWorks Therapeutics in Q2 2025, selling an estimated $365K.
  • Birchview Capital's ten largest holdings make up 57% of its $101M portfolio in Q2 2025.
  • Birchview Capital opened 12 new positions and closed 9 in Q2 2025.
  • Birchview Capital's portfolio value fell 13% quarter-over-quarter to $101M.

Based on Birchview Capital's 13F filing for Q2 2025, filed 14 Aug 2025.